Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBITDA Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of EBITDA Margin data on record, last reported at 6119.28% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 614079.0% year-over-year to 6119.28%; the TTM value through Sep 2025 reached 342.59%, down 7479.0%, while the annual FY2024 figure was 179.88%, 2440.0% down from the prior year.
  • EBITDA Margin reached 6119.28% in Q3 2025 per SGMO's latest filing, down from 97.54% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 21.52% in Q3 2024 and bottomed at 10712.27% in Q1 2024.
  • Average EBITDA Margin over 5 years is 2073.18%, with a median of 207.46% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: tumbled -1072368bps in 2024, then surged 1031932bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 169.58% in 2021, then dropped by -20bps to 203.42% in 2022, then plummeted by -1394bps to 3039.13% in 2023, then surged by 87bps to 399.85% in 2024, then tumbled by -1430bps to 6119.28% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6119.28% in Q3 2025, 97.54% in Q2 2025, and 460.28% in Q1 2025.